Dienogest and deep infiltrating endometriosis: The remission of symptoms is not related to endometriosis nodule remission

Leonardo-Pinto JP, João Paulo Leonardo-Pinto, Joao Paulo Leonardo-Pinto, Benetti-Pinto CL, Cristina Laguna Benetti-Pinto, Cristina Laguna Benetti‐Pinto, Kleber Cursino, Cursino K, Daniela Angerame Yela, Yela DA
European journal of obstetrics, gynecology, and reproductive biology · 2017 · vol. 211 , pp. 108–111 · doi:10.1016/j.ejogrb.2017.02.015 · PMID:28231497 · W2587994610
article OA: closed CC0 ⤵ 59 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-06 ⓘ

This study investigated the relationship between Dienogest treatment and deep infiltrating endometriosis nodules, finding symptom remission did not correlate with nodule remission.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ObjectiveTo evaluate the effectiveness of dienogest in controlling pain caused by deep infiltrating endometriosis (DIE), its influence on the quality of live (QoL) of women affected by the disease, and the effect of the drug on the volume of endometriotic lesions.Study designA prospective cohort study including 30 women with a sonographic diagnosis of DIE (intestinal and posterior fornix) treated with dienogest 2mg per day for 12 months. We evaluated the pain symptoms and the volume of the intestinal and posterior fornix lesions before and after 12 months of use of dienogest. To perform the statistical analysis, we used the Wilcoxon signed-rank test, and the relationship between the data was tested using the Spearman correlation coefficient.ResultsWomen were on average 36.13±6.24years old. Pain symptoms most commonly reported were dyspareunia (83.3%), dysmenorrhea (73.3%), and pelvic pain (66.7%). After 12 months of treatment with dienogest, there was significant improvement of various symptoms (dyspareunia p=0.0093, dysmenorrhea p<0.0001; pelvic pain p=0.0007; and bowel pain p<0.0001), without a reduction in the volume of endometriotic nodules. There were significant improvements in the parameters that comprise the QoL (physical p<0.0001; p=0.0007 psychological) and the self-assessment of QoL (p=0.0069) and health (p=0.0001).ConclusionDienogest is an effective medication to control symptoms of pain related to DIE, even without reducing the volume of DIE nodules.

My notes (saved in your browser only)

Condition tags

endometriosischronic_pelvic_paindie_deep_infiltrating

MeSH descriptors

Endometriosis Hormone Antagonists Intestinal Diseases Nandrolone Pelvic Pain Adult Constipation Constipation Constipation Constipation Endometriosis Endometriosis Endometriosis Female Hormone Antagonists Humans Intestinal Diseases Intestinal Diseases Intestinal Diseases Nandrolone

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (42)

Cited by (50)

Source provenance

europepmc
last seen: 2026-07-26T06:08:39.051465+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:20:37.704673+00:00
License: CC0 · commercial use OK